{"id":11330,"date":"2022-07-01T20:33:33","date_gmt":"2022-07-02T00:33:33","guid":{"rendered":"https:\/\/www.cancerresearch.org\/event\/multiple-myeloma-immunotherapy-where-are-we\/"},"modified":"2022-07-14T15:52:02","modified_gmt":"2022-07-14T19:52:02","slug":"multiple-myeloma-immunotherapy-where-are-we","status":"publish","type":"cri_events","link":"https:\/\/www.cancerresearch.org\/es\/events\/multiple-myeloma-immunotherapy-where-are-we","title":{"rendered":"Multiple Myeloma Immunotherapy: Where Are We?"},"content":{"rendered":"<p style=\"text-align:center\"><iframe loading=\"lazy\" allowfullscreen=\"\" frameborder=\"0\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/_wyhWMWALvM\" width=\"640\"><\/iframe><\/p>\n<p>On September 13, 2016, Alexander M. Lesokhin, MD, discussed immunotherapy treatment options for patients with multiple myeloma, and how close we are to making these treatments available to more patients, including studies in vaccines, monoclonal antibodies, and checkpoint blockade.<\/p>\n<p>Dr. Lesokhin is an assistant attending physician on the Myeloma Service and Immunotherapeutics Core and a member of the Ludwig Collaborative Laboratory at Memorial Sloan Kettering Cancer Center in New York, NY. His research focuses on the ability of cancers to evade the immune system and on developing novel treatments to reverse this process. Lesokhin leads a portfolio of clinical trials testing the clinical and immune effects of immunotherapies in blood cancers. He received his MD from the Albert Einstein College of Medicine, and then went on to complete his residency and oncology fellowship training at Columbia University Medical Center and Memorial Sloan Kettering, respectively.<\/p>\n<p>This webinar is part of the Cancer Research Institute&#39;s webinar series, &quot;Cancer Immunotherapy and You,&quot; which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&amp;A. This series is presented by Genentech and LabAnswer and its employees, with generous support from Abbvie, Celldex Therapeutics, NewLink Genetics, and Regeneron. For more information on this webinar, or to register for upcoming webinars, please visit <a href=\"https:\/\/www.cancerresearch.org\/webinars\" target=\"_blank\" rel=\"noopener\">www.cancerresearch.org\/webinars<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Alexander Lesokhin of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient&#39;s plasma cells.<\/p>\n","protected":false},"featured_media":3772,"template":"","events_categories":[198],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-11330","cri_events","type-cri_events","status-publish","has-post-thumbnail","hentry","events_categories-webinars"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Webinar: Multiple Myeloma Immunotherapy<\/title>\n<meta name=\"description\" content=\"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient&#039;s plasma cells.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Webinar: Multiple Myeloma Immunotherapy\" \/>\n<meta property=\"og:description\" content=\"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient&#039;s plasma cells.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-14T19:52:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/e58621f4-b65e-4637-a3e0-3be85a720de9.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Webinar: Multiple Myeloma Immunotherapy\" \/>\n<meta name=\"twitter:description\" content=\"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient&#039;s plasma cells.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/e58621f4-b65e-4637-a3e0-3be85a720de9.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we\",\"url\":\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we\",\"name\":\"Webinar: Multiple Myeloma Immunotherapy\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/a6b453ea-249c-4d88-9a49-0e7d59573d2a.jpg\",\"datePublished\":\"2022-07-02T00:33:33+00:00\",\"dateModified\":\"2022-07-14T19:52:02+00:00\",\"description\":\"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient's plasma cells.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/a6b453ea-249c-4d88-9a49-0e7d59573d2a.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/a6b453ea-249c-4d88-9a49-0e7d59573d2a.jpg\",\"width\":320,\"height\":208},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Event\",\"item\":\"https:\/\/www.cancerresearch.org\/events\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Multiple Myeloma Immunotherapy: Where Are We?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Webinar: Multiple Myeloma Immunotherapy","description":"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient's plasma cells.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we","og_locale":"es_ES","og_type":"article","og_title":"Webinar: Multiple Myeloma Immunotherapy","og_description":"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient's plasma cells.","og_url":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we","og_site_name":"Cancer Research Institute","article_modified_time":"2022-07-14T19:52:02+00:00","og_image":[{"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/e58621f4-b65e-4637-a3e0-3be85a720de9.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_title":"Webinar: Multiple Myeloma Immunotherapy","twitter_description":"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient's plasma cells.","twitter_image":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/e58621f4-b65e-4637-a3e0-3be85a720de9.jpg","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we","url":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we","name":"Webinar: Multiple Myeloma Immunotherapy","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/a6b453ea-249c-4d88-9a49-0e7d59573d2a.jpg","datePublished":"2022-07-02T00:33:33+00:00","dateModified":"2022-07-14T19:52:02+00:00","description":"Alexander Lesokhin, MD, of Memorial Sloan Kettering Cancer Center, discusses immune-based treatments for a cancer that affects the patient's plasma cells.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/a6b453ea-249c-4d88-9a49-0e7d59573d2a.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/a6b453ea-249c-4d88-9a49-0e7d59573d2a.jpg","width":320,"height":208},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/events\/multiple-myeloma-immunotherapy-where-are-we#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Event","item":"https:\/\/www.cancerresearch.org\/events"},{"@type":"ListItem","position":3,"name":"Multiple Myeloma Immunotherapy: Where Are We?"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events\/11330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_events"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/3772"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=11330"}],"wp:term":[{"taxonomy":"events_categories","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/events_categories?post=11330"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=11330"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=11330"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=11330"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=11330"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=11330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}